Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII

Blood

Volumn 92, Issue 10, 1998, Pages 3701-3709

  Healey, John F ^b   Barrow, Rachel T ^b   Tamim, Hiba M ^b   Lubin, Ira M ^b   Shima, Midori ^b   Scandella, Dorothea ^b   Lollar, Pete ^a  

^a EMORY UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; EPITOPE; GLUCOSE; MONOCLONAL ANTIBODY; PHOSPHOLIPID; POLYCLONAL ANTIBODY; THREONINE; TYROSINE; VALINE; VON WILLEBRAND FACTOR;

ARTICLE; BINDING SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYBRID; NONHUMAN; PRIORITY JOURNAL; SWINE;

EID: 0032533220     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.10.3701.422k22_3701_3709     Document Type: Article

References (55)

1. Hoyer LW, Scandella D: Factor VIII inhibitors: Structure and function in autoantibody and hemophilia A patients. Semin Hematol 31:1, 1994
2. Fulcher CA, Mahoney SD, Roberts JR, Kasper CK, Zimmerman TS: Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 82:7728, 1985
3. Scandella D, Mahoney SD, Mattingly M, Roeder D, Timmons L, Fulcher CA: Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 85:6152, 1988
4. Scandella D, Mattingly M, de Graaf S, Fulcher CA: Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 74:1618, 1989
5. Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW: A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 67:665, 1992
6. Scandella D, Mattingly M, Prescott R: A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies which bind to A2. Blood 82:1767, 1993
7. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E: Some human inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248-2312 which overlap a phospholipid binding site. Blood 86:1811, 1995
8. Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries J, Hurst D, Bray G, Scandella D, Recombinate and Kogenate Study Groups: The inhibitory antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with fVIII autoantibodies. Blood 89:3663, 1997
9. Lubin IM, Healey JF, Scandella D, Runge MS, Lollar P: Elimination of a major inhibitor epitope in factor VIII. J Biol Chem 269:8639, 1994
10. Healey JF, Lubin IM, Nakai H, Saenko EL, Hoyer LW, Scandella D, Lollar P: Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 270:14505, 1995
11. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ: Structure of human factor VIII. Nature 312:337, 1984
12. Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Pass DN, Hewick RM: Molecular cloning of a cDNA encoding human antihaemophilia factor. Nature 312:342, 1984
13. Fulcher CA, Lechner K, Mahoney SdG: Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 72:1348, 1988
14. Eaton D, Rodriguez H, Vehar GA: Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 25:505, 1986
15. Parker ET, Pohl J, Blackburn MN, Lollar P: Subunit structure and function of porcine factor Xa-activated factor VIII. Biochemistry 36:9365, 1997
16. Lollar P, Parker CG: Subunit structure of thrombin-activated porcine factor VIII. Biochemistry 28:666, 1989
17. Lollar P, Parker ET: Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 266:12481, 1991
18. Curtis JE, Helgerson SL, Parker ET, Lollar P: Isolation and characterization of thrombin-activated human factor VIII. J Biol Chem 269:6246, 1994
19. a from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 266:8957, 1991
20. Lajmanovich A, Hudry-Clergeon G, Freyssinet JM, Marguerie G: Human factor VIII procoagulant activity and phospholipid interactions. Biochim Biophys Acta 678:132, 1981
21. Andersson LO, Brown JE: Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J 200:161, 1981
22. Fay PJ, Coumans J-V, Walker FJ: von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 266:2172, 1991
23. Cornu P, Larrieu M-J, Caen J, Bernard J: Transfusion studies in von Willebrand's disease: Effect on bleeding time and factor VIII. Br J Haematol 9:189, 1963
24. Biggs R, Matthews JM: The treatment of hemorrhage in von Willebrand's disease and the blood level of factor VIII (AHG). Br J Haematol 9:203, 1963
25. Tuddenham EG, Lane RS, Rotblat F, Johnson AJ, Snape TJ, Middleton S, Kernoff PB: Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 52:259, 1982
26. Brinkhous KM, Sandberg H, Garris JB, Mattson C, Palm M, Griggs T, Read MS: Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusion into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 82:8752, 1985
27. Lollar P, Parker ET, Curtis JE, Helgerson SL, Hoyer LW, Scott ME, Scandella D: Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest 93:2497, 1994
28. Zhong D, Scandella D: Epitope of a hemophilia A inhibitor antibody overlaps the factor VIII binding site for factor IX. Blood 88:324a, 1996 (abstr, suppl 1)
29. Arai M, Scandella D, Hoyer LW: Molecular basis of factor-VIII inhibition by human antibodies - Antibodies that bind to the factor-VIII light chain prevent the interaction of factor-VIII with phospholipid. J Clin Invest 83:1978, 1989
30. Barrowcliffe TW, Kemball-Cook G, Gray E: Binding to phospholipid protects factor VIII from inactivation by human antibodies. J Lab Clin Med 101:34, 1983
31. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H: A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 69:240, 1993
32. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D: A role for the C2 domain of factor binding to von Willebrand factor. J Biol Chem 269:11601, 1994
33. 1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 263:5230, 1988
34. Leyte A, Verbeet MP, Brodniewicz-Proba T, van Mourik JA, Mertens K: The interaction between human blood-coagulation factor VIII and von Willebrand factor. Biochem J 257:679, 1989
35. Shima M, Yoshioka A, Nakai H, Tanaka I, Sawamoto Y, Kamisue S, Terada S, Fukui H: Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor. Int J Hematol 54:515, 1991
36. 1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 266:740, 1991
37. Lollar P, Hill-Eubanks DC, Parker CG: Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 263:10451, 1988
38. Saenko EL, Scandella D: The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem 272:18007, 1997
39. Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EGD, Vehar GA, Lawn RM: Expression of active human factor VIII from recombinant DNA clones. Nature 312:330, 1984
40. Horton RM, Ho SN, Pullen JK, Hunt HD, Cai Z, Pease LR: Gene splicing by overlap extension. Methods Enzymol 217:270, 1993
41. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
42. Bowie EJW, Owen CA: The clinical and laboratory diagnosis of hemorrhagic disorders, in Ratnoff OD, Forbes CD (eds): Disorders of Hemostasis. Orlando, FL, Grune and Stratton, 1984, p 43
43. Kasper CK, Aledort LM, Counts RB, Edson JR, Frantatoni J, Gree D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eyes J: A more uniform measurement of factor VIH inhibitors. Thromb Diath Haemorrh 34:869, 1975
44. Healey JF, Lubin IM, Lollar P: The cDNA and derived amino acid sequence of porcine factor Vin. Blood 88:4209, 1996
45. Lind P, Larsson K, Spira J, Sydow-Backman M, Almstedt A, Gray E, Sandberg H: Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur J Biochem 232:19, 1995
46. Lollar P, Fay PJ, Pass DN: Factor VIII/factor VIIIa. Methods Enzymol 222:128, 1993
47. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H: A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 69:240, 1993
48. Sawamoto Y, Prescott R, Zhong D, Saenko EL, Mauser-Bunschoten E, Peerlinek K, van den Berg M, Scandella D: C2 domain restricted epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost (in press)
49. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS: Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 75:1999, 1990
50. Gilbert GE, Baleja JD: Membrane-binding peptide from the C2 domain of factor VIII forms an amphipathic structure as determined by NMR spectroscopy. Biochemistry 34:3022, 1995
51. Gilbert GE, Furie BC, Furie B: Binding of human factor VIII to phospholipid vesicles. J Biol Chem 265:815, 1990
52. Saenko EL, Scandella D: A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem 270:13826, 1995
53. McMullen BA, Fujikawa K, Davie EW, Hedner U, Ezban M: Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A). Prot Sci 4:740, 1995
54. Gilles JGG, Arnout J, Vermylen J, Saint-Remy J-MR: Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 82:2452, 1993
55. Ortel TL, Quinn-Allen MA, Keller FG, Peterson JA, Larocca D, Kane WH: Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras. J Biol Chem 269:15898, 1994